Fiona C. Thistlethwaite, MB BChir – FDA 483, May 1, 2026

An FDA inspection of Fiona C. Thistlethwaite, MB BChir, a clinical investigator in Manchester, United Kingdom, revealed significant deviations from good clinical practices during a Phase 2 clinical trial. The investigator failed to conduct a protocol-required procedure prior to dosing a subject and did not report a subject's condition as an adverse event. These findings indicate serious non-compliance with the investigational plan.